Diagnostic Performance of 99 mTc-Sestamibi SPECT/CT and 18F-Choline PET/CT in Locating Hyperfunctioning Parathyroid Glands in Patients with Primary Hyperparathyroidism
Nuklearmedizin - NuclearMedicine · 01.10.2025 · 64 (05) · 308-312
DOI: 10.1055/a-2694-8426 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.10.2025. Verfasst von Ante Mandic und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina. Hauptthemen laut MEDLINE: Technetium Tc 99m Sestamibi, Hyperparathyroidism, Primary, Choline, Positron Emission Tomography Computed Tomography. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
This study aimed to assess the diagnostic performance of 99mTc-sestamibi SPECT/CT and 18F-choline PET/CT in detecting hyperfunctioning parathyroid glands in patients undergoing surgery for primary hyperparathyroidism (PHPT). A retrospective analysis was conducted on patients who underwent PHPT-related surgery between April 2019 and May 2022. The study focused on patients undergoing either 99mTc-sestamibi SPECT/CT (81 patients) or 18F-choline PET/CT (33 patients) scans before surgery to pinpoint hyperfunctioning parathyroid gland(s). In the majority of patients, 18F-choline PET/CT was performed after negative or inconclusive findings on 99mTc-sestamibi SPECT/CT. Pathohistological reports were utilized as the reference standard for evaluating the accuracy of the imaging findings. The study encompassed 83 patients (70 females, 84.3 %) with an average age of 57.2 years (24–80 years). The pathohistological analysis identified a total of 98 glands. In a per-lesion analysis, the detection rate of 99mTc-sestamibi SPECT/CT was 57 % (95 % CI 45.3–68.1), while the detection rate of 18F-choline PET/CT was 90.3 % (95 % CI 74.3–98.0). The results of our study showed the significant usefulness of 18F-choline PET/CT in patients with negative or inconclusive results of 99mTc-sestamibi SPECT/CT in accurately locating hyperfunctioning parathyroid glands in PHPT patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
- University of Zagreb School of Medicine, Zagreb, Croatia.
- Department of Endocrinology, University Hospital Centre Zagreb, Zagreb, Croatia.
ORCID-Profile: Ante Mandic, Darko Kastelan
Zitieren
APA
Mandic, A., Kraljevic, I., Skoric Polovina, T., Zibar Tomsic, K., Dusek, T., Balasko, A., Solak, M., & Kastelan, D. (2025). Diagnostic Performance of 99 mTc-Sestamibi SPECT/CT and 18F-Choline PET/CT in Locating Hyperfunctioning Parathyroid Glands in Patients with Primary Hyperparathyroidism. Nuklearmedizin - NuclearMedicine, 64(05), 308-312. https://doi.org/10.1055/a-2694-8426
Vancouver
Mandic A, Kraljevic I, Skoric Polovina T, Zibar Tomsic K, Dusek T, Balasko A, et al. Diagnostic Performance of 99 mTc-Sestamibi SPECT/CT and 18F-Choline PET/CT in Locating Hyperfunctioning Parathyroid Glands in Patients with Primary Hyperparathyroidism. Nuklearmedizin - NuclearMedicine. 2025;64(05):308-312. doi:10.1055/a-2694-8426
BibTeX
@article{Mandic2025,
author = {Mandic, Ante and Kraljevic, Ivana and Skoric Polovina, Tanja and Zibar Tomsic, Karin and Dusek, Tina and Balasko, Annemarie and Solak, Mirsala and Kastelan, Darko},
title = {Diagnostic Performance of 99 mTc-Sestamibi SPECT/CT and 18F-Choline PET/CT in Locating Hyperfunctioning Parathyroid Glands in Patients with Primary Hyperparathyroidism},
journal = {Nuklearmedizin - NuclearMedicine},
year = {2025},
volume = {64},
number = {05},
pages = {308--312},
doi = {10.1055/a-2694-8426}
}
EUVIMED